FONT-SIZE Plus   Neg

Novartis' Exjade Receives Approval From The European Commission

Novartis AG (NVS: Quote) Friday said it has received approval from the European Commission for Exjade, an oral drug used to subside iron overload in patients undergoing chelation therapy for non-transfusion-dependent thalassemia, or NTDT, syndrome.

The approval is based on results from the placebo-controlled study of iron chelation in NTDT patients.

Thalassemia is a genetic disorder affecting red blood cell production, and thereby causing anemia. NTDT, unlike many other types of thalassemia, don't receive regular transfusion, subsequently resulting in a chronic iron overload.

Certain other health complication including liver fibrosis and cirrhosis, blood clots, bone disease, pulmonary hypertension, can also lead to higher iron concentration.

At least three quarters of a million people worldwide have NTDT syndromes, according to published studies.

In the pivotal study, named THALASSA, Exjade showed a significant dose-dependent decrease in concentration of iron-burden in the body as well as liver, compared to placebo. Meanwhile, the overall adverse event rate for Exjade was similar to the placebo arm.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
France is reported to be considering new laws that will make Internet companies like Google and Facebook liable for social media posts inciting terrorism. The FCC has warned Marriott and other hotel chains to stop the "disturbing trend" of illegally blocking guests' private wi-fi. Marriott, which was fined $600,000 for blocking personal hotspots in hotel rooms and conference spaces, recently stopped the practice after a storm of criticism on social... Apple Inc. said Tuesday after the markets closed that its first quarter profit rose 38% from last year, driven by all time record revenue from iPhone and Mac sales as well as record performance of its App Store. The company's quarterly earnings per share also breezed past Wall Street expectations as did its quarterly sales.
comments powered by Disqus
Trade NVS now with 
Follow RTT